The aim of this study was to assess the major risk factors for venous thromboembolism (VTE) in Chinese patients with ovarian cancer and to explore optimal methods of prophylaxis and treatment.
Introduction
Venous thromboembolism (VTE), which comprises deep vein thrombosis (DVT) and its complication of pulmonary embolism (PE), is a multifactorial disease and is considered to be the second most common cause of death in patients with active cancer. [1, 2] There is little information on how to treat perioperative events, especially in preoperative ovarian cancer patients with VTE. The association between VTE and malignancy was first recognized by Trousseau, who described thrombophlebitis as the presenting sign of visceral malignancy. Since then, VTE has received growing attention as a potentially catastrophic event and one of the lethal perioperative complications. Unfortunately, despite increased monitoring and prevention of thrombosis in these tumor patients, the incidence of VTE has not been reduced but has increased over past years. [3] Svendsen and Karwinski [4] found that only 12% of patients with malignant tumors survive for more than 1 year from the first diagnosis of VTE. There are currently no large-scale statistical data reported for the incidence of VTE after surgery for malignant ovarian tumors. Overall, the incidence of VTE is significantly increased after surgery in patients with gynecological malignancies. According to previous reports, [5, 6] the rate of DVT in patients with gynecologic malignancy ranges from 7% to 45%, whereas the rate of PE ranges between 1% and 2.6%. Abdominal and pelvic tumors are closely linked with the occurrence of VTE. [7] A 14-year study [8] of male and female cancer patients hospitalized in the United Kingdom found that ovarian cancer patients with VTE account for approximately 4%, which was the second highest of all malignancies. Patients with ovarian cancer are particularly prone to thrombosis, due to late diagnosis, extensive spread, timeconsuming surgery, intraoperative and postoperative immobilization, and extrinsic deformation of the vascular wall.
There are many risk factors for VTE that have been reported in different studies, [11, 12] such as increasing age, venous stasis with or without varicose veins, malignant disease, long-term immobility, history of VTE, severe infection, chronic renal failure, congestive heart failure, history of myocardial infarction, inflammatory bowel disease, more than 3 prior pregnancies, the peripartum period, hormone replacement therapy, the use of oral contraceptives, and obesity. In a word, previous studies, including the study from Ye et al [13] from China, almost focused on the high-risk factors, incidence, and timing of VTE. There is little information on how to treat preoperative ovarian cancer patients with VTE. The purpose of our present study was not only to identify specific risk factors for VTE in patients with ovarian cancer but also to explore how to treat VTE and prevent fatal complications during the perioperative period.
Materials and methods

Data collection
A retrospective analysis of 388 patients with ovarian cancer who underwent surgical treatment in Qilu Hospital of Shandong University, from January 2014 to January 2017, was conducted. Preoperative clinical data collected included age, medical history, type of thrombosis, complications, laboratory tests such as D-dimer, platelet and cancer antigen 125 (CA 125), Federation International of Gynecology and Obstetrics (FIGO) stage, smoking status at diagnosis, and route of surgery (abdominal or laparoscopic). Preoperative or postoperative chemotherapy, operation time, intraoperative blood loss, postoperative pathological results, and any preventive methods were also analyzed, the latter of which included preoperative and postoperative application of low molecular weight heparin sodium injection (LMWH also named Qizheng produced by Qilu Pharmaceutical Co. Ltd). All the patients had expert pathology reviewed. Cancers were staged according to the 2014 FIGO guidelines. All patients were followed up for at least 6 months from the time of first diagnosis of ovarian cancer to the last chemotherapy treatment.
All patients with a likely diagnosis of ovarian cancer were routinely checked by ultrasound (Philips iU22 Ultrasound System) to exclude bilateral lower extremity DVT. Symptomatic patients underwent pulmonary computed tomography (CT) angiography to exclude PE. If a patient had pain in a lower extremity after operation, they underwent ultrasound examination. This study was approved by the Research Ethics Board of Qilu Hospital, Shandong University.
Treatment
Preoperative patients with VTE were treated with LMWH for 2 weeks followed by oral warfarin or rivaroxaban (Xarelto) for at least 1 month. Chemotherapy with carboplatin paclitaxel was recommended for 2 or 3 courses, after which cytoreductive surgery was performed.
Two patients were treated with inferior vena cava filter implantation before surgery, with the filter removed 3 months after surgery.
After 24 hours of cytoreductive surgery, a prophylatic VTE regimen was given to all patients without contraindications. They were given subcutaneous injections of 5000 u LMWH every 12 hours for at least 7 days.
Statistical analysis
Statistical analysis was performed using SPSS 22.0 (SPSS Inc., Chicago, IL). The differences between the 2 groups were compared using an independent-sample t test and the Chi-square test. Univariate analysis was performed to determine the association between different risk factors and VTE, and multivariate logistic regression analysis was used to identify significant risk factors for VTE. A probability value of < 0.05 was considered to indicate statistical significance.
Results
Risk factors for VTE in the patients with ovarian cancer
The clinical characteristics of the 2 groups are listed in Table 1 . Among the 388 patients finally diagnosed with ovarian cancer, were PE merged with detectable DVT, including 1 patient with a subclavian vein thrombosis. The remaining 27 patients had a DVT in the left leg (n = 7), 8 in the right leg, and 12 in both legs. Twenty cases were serous adenocarcinoma, 4 mucinous adenocarcinoma, 5 endometrioid adenocarcinoma, and 6 were clear cell carcinoma. The average patient age was 57.6 years. The clinical data of the 2 groups are listed in Table 1 . The median Ddimer value in VTE group is 1.39 mg/mL.
The results of univariate and multivariate analysis of preoperative risk factors for VTE are listed in Table 2 . There was a significant difference in age, cardiovascular comorbidity, tumor diameter, platelet count (PLT), and D-dimer on univariate analysis, while on multivariate analysis, there was a significant association with age >55 years, PLT >300 Â 10 9 /L, D-dimer >0.5 mg/mL, and tumor diameter >10 cm, with the risk ratios being 13.11, 3.987,17.317, and 4.930, respectively (Table 2 ).
In addition, we also analyzed perioperative risk factors of VTE. Length of surgery, use of chemotherapy, and no use of postoperative anticoagulation were significantly related to postoperative VTE on univariate analysis (Table 3) , but there was no significant difference according to estimated blood loss (EBL), type of surgery, and need for blood transfusion. Multivariate analysis revealed that a D-dimer >0.5 mg/mL and an operative time >150 minutes were independent risk factors for postoperative VTE with the risk ratios being 6.098 and 7.528 (Table 3) .
Outcomes in preoperative patients with PE after treatment with anticoagulation therapy and chemotherapy with carboplatin paclitaxel
The 4 preoperative patients with PE received 2 courses of chemotherapy and anticoagulation with LMWH. All 4 patients' PE disappeared on imaging, and their ascites and mass sizes also decreased. Furthermore, they were all treated with cytoreductive surgery with satisfactory results.
Discussion
VTE prophylaxis is particularly important for surgical oncologists given the high rate of DVT in patients with malignancy. When compared with cervical cancer and endometrial cancer, ovarian cancer patients are more likely to have VTE. [8, 14] In our present study, the incidence of VTE during the perioperative period for ovarian cancer was 9.02%, which was lower than that reported previously, [15] [16] [17] possibly due to the use of LMWH in all patients during the perioperative period and not including asymptomatic thrombosis diagnosed on routine testing.
Many risk factors that increase the occurrence of VTE have been reported, [11, 12] such as age, a history of VTE, more than 3 previous pregnancies, and cardiovascular disease. We found that age more than 55 years, larger tumors, high PLT, and high Ddimer levels were independent risk factors for the formation of VTE. D-dimer levels is not only in correlation with ovarian cancer prognosis but also with VTE. [18] A high D-dimer level is helpful in screening preoperative VTE, especially silent VTE. If a patient's D-dimer value greater than 0.5 mg/mL needs to be vigilant about VTE risk rather than diagnosis of VTE according to our univariate and multivariate analysis, the cutoff value of D-dimer for predictive VTE is still controversial. Ay et al [19] suggested the cutoff for elevated D-dimer was greater than 1.44 mg/mL for various cancers; however, Satoh et al [20] and Kawaguchi et al [21] recommended that the cutoff value could be greater than 1.5 mg/ mL in ovarian cancer. In our present study, we found that the median value of D-dimer was 1.39 mg/mL. Our result is almost the same as mentioned above. Larger tumors compress the pelvic vasculature, impacting pelvic and lower limb blood circulation, thereby increasing blood viscosity, resulting in VTE. Surprisingly, both diabetes and smoking were not significant risk factors for VTE. This may be because there were few diabetic patients and few smokers in our study. The stage of tumor also had some influence on the incidence of VTE in our study. In a study of 641 cases, [22] clear cell and high-grade undifferentiated adenocarcinomas were the most likely to result in VTE, the former related perhaps to lymph node spread and hypercoagulability.
For the treatment-related factors, in our study, adjuvant chemotherapy was found to be an independent risk factor for VTE. Chemotherapy has played a significant role in improving the prognosis of ovarian cancer, but it is also a risk factor for VTE. Cisplatin is known to be associated with a variety of toxic effects, including VTE, hypertension, myocardial infarction, and stroke. The mechanism of VTE related to chemotherapy is not very clear, but some of the effects of chemotherapy have been described. [23] Ratib et al [8] found patients who received chemotherapy had a higher incidence of VTE than those who did not. The 4 PE preoperative patients who received chemotherapy with cisplatin paclitaxel for 2 courses, and anticoagulation with LMWH in our study all had complete disappearance of their PE, their ascites and mass sizes decreased, and underwent optimal cytoreductive surgery, with no new VTE events. Large tumors or massive ascites in ovarian cancer may compress the intrapelvic veins and enhance the risk of DVT even before surgery. [20] Thus, we recommend that any patient who is diagnosed preoperatively should be treated with chemotherapy and anticoagulation before cytoreductive surgery.
In the present study, the surgical time of the VTE group was significantly longer than that of the non-VTE patients, which was in keeping with other studies. [24, 25] There are several differences between gynecologic tumor surgery and general surgical procedures with the former patients often requiring special procedures, such as dissection of lymph nodes, and pelvic and peritoneal metastases, resulting in prolonged operative time, and an increased incidence of VTE. The primary mechanism of VTE in this situation is probably vascular injury caused by the dissection with exposed vascular endothelial cells and factor III leak, leading to the release of cytokines, thereby activating the coagulation process. [26] [27] [28] [29] [30] Standard techniques for prevention of VTE include the prophylactic use of LMWH, intermittent calf compression after surgery, and early ambulation. [31, 32] 5. Conclusion VTE may be prevented by careful assessment of ovarian cancer patients with the risk factors identified in this study. Ovarian cancer patients who are older than 55 years have cardiovascular complications, who receive adjuvant chemotherapy, and have high D-dimer values and high PLTs should undergo further investigations to exclude VTE. Furthermore, the use of perioperative anticoagulants, as well as a shortened surgery time, should reduce the incidence. For patients with ovarian cancer who have been diagnosed with thrombosis before surgery, adjuvant chemotherapy and anticoagulant drugs can be used to control the extension and spread of both the thrombosis and the cancer.
